Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck and : Biothera Pharmaceuticals Announces Presentations on Imprime PGG at Three Upcoming Healthcare Conferences

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/03/2017 | 01:45pm CEST

Release date- 02102017 - EAGAN, MN - Biothera Pharmaceuticals, Inc. today announced that it will present new research at three upcoming healthcare conferences for Imprime PGG, Biothera's novel phase 2 cancer immunotherapy.

These presentations will provide data strengthening the scientific foundation for the use of Imprime PGG in combination with immune checkpoint inhibitors. The high profile late-breaking session of the AACR-NCI- EORTC will feature initial translational research from Biothera's ongoing phase 2 clinical study combining Imprime PGG and Merck's anti-PD-1 antibody, Keytruda, for the treatment of biomarker-positive patients with triple negative breast cancer or metastatic melanoma.

About Biothera Pharmaceuticals Inc.

Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a Phase 2 cancer immunotherapy that enhances the efficacy of anti-cancer immune response in combination with immune checkpoint inhibitor, tumor-targeting and anti-angiogenesis antibodies. Biothera Pharmaceuticals has clinical research agreements with Merck to evaluate Imprime PGG and KEYTRUDA in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has demonstrated a favorable safety profile in more than 400 subjects and signals of activity in multiple combinations and tumor types.

Contact:

David Walsh

Tel: 651-256-4606

Email: [email protected]

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
10/16 ASTRAZENECA : Pharma and medtech industries prepare for hard Brexit
10/16 MERCK AND : Makes $3 Million Charitable Donation to Support Swim Across America
10/16 MERCK AND : Joins with the American Liver Foundation to Educate U.S. Veterans on..
10/16 BERGENBIO : BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured..
10/16 BERGENBIO : BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured..
10/13 MERCK AND : Salk Researchers Awarded $2.5 Million for Innovative Pancreatic Canc..
10/13 MERCK AND : Provides Update on Anacetrapib Development Program
10/12 MERCK : Makes $3 Million Charitable Donation to Support Swim Across America
10/12 MERCK : Joins with the American Liver Foundation to Educate U.S. Veterans on Chr..
10/12 MERCK AND : Bedell Frazier Investment Counseling Has Increased Its Position in W..
More news
News from SeekingAlpha
11:51a Dynavax Reports More Good News
10/16 Merck's Risk/Reward Is Compelling
10/16 Merck Pulls The Plug On Cholesterol Drug
10/16 President Trump at it again with comments on "out of control" drug prices
10/16 SANOFI : Upward Trajectory In 2017
Financials ($)
Sales 2017 40 272 M
EBIT 2017 13 680 M
Net income 2017 5 795 M
Debt 2017 8 102 M
Yield 2017 2,98%
P/E ratio 2017 31,60
P/E ratio 2018 18,84
EV / Sales 2017 4,49x
EV / Sales 2018 4,42x
Capitalization 173 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 69,6 $
Spread / Average Target 9,9%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY7.68%172 751
JOHNSON & JOHNSON18.42%365 346
NOVARTIS13.23%226 956
ROCHE HOLDING LTD.5.20%215 359
PFIZER11.88%214 265
AMGEN25.17%132 728